Accelerate your oncology R&D with quality biospecimens & data
We are a key resource for
Pharma & biotech
Reliable & robust assay performance starts with high quality specimens. Our ethically approved anonymized clinical samples include annotated histopathological and molecular data plus clinical follow-up information.
Diagnostics companies
Our specimens and control tissues make us a key resource for diagnostic companies specializing in either histologic or nucleic acid assays, NGS, multiplex assays, and IHC using all prevalent platforms.
AI companies
TriStar offers a large searchable library of digital images including H&E and IHC stained tissues and associated metadata for use in algorithm development.
Multi-spectral spatial analysis of pre-treatment NSCLC cohort with 2nd line immunotherapy response data using MOTiFTM lung cancer PD-1/PD-L1 panel (Akoya).
Representative analysis of TMA cores from responders to immune checkpoint inhibitors (ICI; top row) and non-responders (lower row). Volcano plot indicates enrichment & significance of cellular interactions - for example, between CD68+ and PD-1+/FoxP3+ cells in ICI-refractory tumors. Such studies can provide early insights into predictive biomarkers associated with response to ICI.
An expansive collection of unique tissue microarrays with extensive follow-up & molecular data
Scientifically relevant TMAs for your biomarker research developed from our strategically collected human tissue samples & collaborations
High quality tissues deliver high quality research
Our samples are well-suited to IHC, RNA-ISH, and NGS platforms.
Integrated biomarker services – samples, annotated clinical & molecular data combined with expert CRO capabilities.
TriStar offers integrated biomarker services complete with samples, annotated clinical & molecular data and expert CRO capabilities
Featured Applications
An industry-experienced scientific team to work with you to customize a fit-for-purpose biospecimen, data, and/or integrated services solution
Our approach begins with our customers’ science.
We focus our acquisition on patient cohorts that meet the needs of biopharma, clinical, and translational researchers.
Featured Resources
Publications
Publications
Digital Spatial Profiling Mar-23
Multi-omic and spatial dissection of immunotherapy response groups in non-small cell lung cancer
Digital Spatial Profiling Apr-23
Single-cell spatial proteomic analysis of the tumor microenvironment in treatment naïve NSCLC samples with immunotherapy treatment and response data